Arbutus Biopharma Corporation posted an updated corporate presentation on November 12, 2026.
ABUS · Arbutus Biopharma Corp · Documents
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Arbutus Biopharma Corporation said the FDA lifted its clinical hold on AB-101’s IND application in October 2026, allowing additional clinical development in the United States.
Arbutus Biopharma reported net income of $59.1 million for the quarter ended September 30, 2026, compared with a net loss of $7.7 million a year earlier. It completed a tender offer in early October 2026, buying 46 million shares at $5.00 per share and returning $230 million to shareholders. Cash, cash equivalents and marketable securities were $337.5 million as of September 30, 2026.
The FDA notified the company that the clinical hold on the IND application for AB-101, its oral PD-L1 inhibitor, has been removed, allowing additional clinical development in the United States. Arbutus is evaluating next steps for AB-101's continued development.
Arbutus Biopharma Corporation accepted 46,000,000 Shares at US$5.00 per Share, an aggregate US$230 million purchase price representing approximately 23 percent of its outstanding Shares; settlement is expected on or about October 5, 2026.
Arbutus expects to purchase 46,000,000 Shares at US$5.00 per Share for an aggregate US$230 million, representing approximately 23% of issued and outstanding Shares; the offer was oversubscribed, so tendered shares will be prorated.